992 related articles for article (PubMed ID: 7605349)
1. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Mechoulam R; Ben-Shabat S; Hanus L; Ligumsky M; Kaminski NE; Schatz AR; Gopher A; Almog S; Martin BR; Compton DR
Biochem Pharmacol; 1995 Jun; 50(1):83-90. PubMed ID: 7605349
[TBL] [Abstract][Full Text] [Related]
2. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity.
Ben-Shabat S; Fride E; Sheskin T; Tamiri T; Rhee MH; Vogel Z; Bisogno T; De Petrocellis L; Di Marzo V; Mechoulam R
Eur J Pharmacol; 1998 Jul; 353(1):23-31. PubMed ID: 9721036
[TBL] [Abstract][Full Text] [Related]
3. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes.
Lee M; Yang KH; Kaminski NE
J Pharmacol Exp Ther; 1995 Nov; 275(2):529-36. PubMed ID: 7473135
[TBL] [Abstract][Full Text] [Related]
4. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells.
Ouyang Y; Hwang SG; Han SH; Kaminski NE
Mol Pharmacol; 1998 Apr; 53(4):676-83. PubMed ID: 9547358
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
6. 2-Arachidonoylglycerol and the cannabinoid receptors.
Sugiura T; Waku K
Chem Phys Lipids; 2000 Nov; 108(1-2):89-106. PubMed ID: 11106784
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid properties of methylfluorophosphonate analogs.
Martin BR; Beletskaya I; Patrick G; Jefferson R; Winckler R; Deutsch DG; Di Marzo V; Dasse O; Mahadevan A; Razdan RK
J Pharmacol Exp Ther; 2000 Sep; 294(3):1209-18. PubMed ID: 10945879
[TBL] [Abstract][Full Text] [Related]
8. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
9. Endogenous cannabinoid ligands--chemical and biological studies.
Mechoulam R; Ben Shabat S; Hanus L; Fride E; Vogel Z; Bayewitch M; Sulcova AE
J Lipid Mediat Cell Signal; 1996 Sep; 14(1-3):45-9. PubMed ID: 8906544
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of endogenous cannabinoids.
Martin BR; Mechoulam R; Razdan RK
Life Sci; 1999; 65(6-7):573-95. PubMed ID: 10462059
[TBL] [Abstract][Full Text] [Related]
11. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
Reggio PH; Wang T; Brown AE; Fleming DN; Seltzman HH; Griffin G; Pertwee RG; Compton DR; Abood ME; Martin BR
J Med Chem; 1997 Sep; 40(20):3312-8. PubMed ID: 9379452
[TBL] [Abstract][Full Text] [Related]
12. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
[TBL] [Abstract][Full Text] [Related]
13. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
14. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.
Hanus L; Abu-Lafi S; Fride E; Breuer A; Vogel Z; Shalev DE; Kustanovich I; Mechoulam R
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3662-5. PubMed ID: 11259648
[TBL] [Abstract][Full Text] [Related]
15. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves.
Ishac EJ; Jiang L; Lake KD; Varga K; Abood ME; Kunos G
Br J Pharmacol; 1996 Aug; 118(8):2023-8. PubMed ID: 8864538
[TBL] [Abstract][Full Text] [Related]
19. Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors.
Paria BC; Ma W; Andrenyak DM; Schmid PC; Schmid HH; Moody DE; Deng H; Makriyannis A; Dey SK
Biol Reprod; 1998 Jun; 58(6):1490-5. PubMed ID: 9623610
[TBL] [Abstract][Full Text] [Related]
20. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
